Cat. No：GM-87352MAB
Product：Anti-CLDN18.2 hIgG1 Reference Antibody (IMAB362)
Cat. No：GM-87352MAB
Product：Anti-CLDN18.2 hIgG1 Reference Antibody (IMAB362)
GM-87352MAB-1mg / 1 mg
GM-87352MAB-5mg / 5 mg
GM-87352MAB-25mg / 25 mg
GM-87352MAB-50mg / 50 mg
GM-87352MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target CLDN18.2
Clone IMAB362
Alternative Names /
Source/Isotype Human IgG1(K214R/D356E/L358M),Kappa
Application /
Description The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer. CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors. With its specific expression pattern, CLDN18.2 has become a unique molecule for targeted therapy in different cancers, especially in GC; for example, agents such as zolbetuximab (claudiximab, IMAB362), a monoclonal antibody (mAb) against CLDN18.2, have been developed.
Formulation phosphate-buffered solution, pH 7.4.
Cat. No：GM-87352MAB
Product：Anti-CLDN18.2 hIgG1 Reference Antibody (IMAB362)
GM-87352MAB-1mg / 1 mg
GM-87352MAB-5mg / 5 mg
GM-87352MAB-25mg / 25 mg
GM-87352MAB-50mg / 50 mg
GM-87352MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target CLDN18.2
Clone IMAB362
Alternative Names /
Source/Isotype Human IgG1(K214R/D356E/L358M),Kappa
Application /
Description The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and development of various primary malignant tumors, such as gastric cancer/gastroesophageal junction (GC/GEJ) cancer, breast cancer, colon cancer, liver cancer, head and neck cancer, bronchial cancer and non-small-cell lung cancer. CLDN18.2 participates in the proliferation, differentiation and migration of tumor cells. Recent studies have identified CLDN18.2 expression as a potential specific marker for the diagnosis and treatment of these tumors. With its specific expression pattern, CLDN18.2 has become a unique molecule for targeted therapy in different cancers, especially in GC; for example, agents such as zolbetuximab (claudiximab, IMAB362), a monoclonal antibody (mAb) against CLDN18.2, have been developed.
Formulation phosphate-buffered solution, pH 7.4.
